Turning Point Therapeutics (TPTX) News Today → HUGE BUY ALERT: Move Fast, Musk... (From Stansberry Research) (Ad) Free TPTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative February 17, 2024 | wsj.comTurning Point Brands Inc.February 12, 2024 | bbc.co.ukAlzheimer’s: A Turning Point?February 10, 2024 | investing.comTurning Point Brands Inc (TPB)February 10, 2024 | benzinga.comCormorant Asset Management, LP's Net WorthJanuary 15, 2024 | bbc.co.ukSolving quadratic equations - EdexcelDecember 19, 2023 | morningstar.comCOP15: A Turning Point for Investor Approaches to BiodiversityDecember 16, 2023 | bbc.comTurning Point USA: Are conservatives fighting back on campus?July 29, 2023 | ft.comTattoos have reached a turning point at workJuly 11, 2023 | newsweek.comTurning Point USAJune 23, 2023 | health.usnews.comTurning Point HospitalJune 5, 2023 | bbc.co.ukCan Vinicius episode be a turning point in football’s racism battle?May 24, 2023 | usnews.comTurning Point Secondary SchoolApril 12, 2023 | ca.finance.yahoo.com2023 could be turning point for office-to-housing conversions: ColliersMarch 22, 2023 | theguardian.comThe invasion of Iraq was a turning point on to a path that led towards UkraineMarch 22, 2023 | news.yahoo.comPutin's arrest warrant is turning point – ZelenskyyMarch 22, 2023 | foxnews.comZelenskyy: Putin's arrest warrant marks 'turning point,' he’ll be held responsible for 'every destroyed life'March 21, 2023 | uk.news.yahoo.com'Deposit return scheme can be turning point in litter battle'March 21, 2023 | news.yahoo.com2023 may be turning point in impact of sanctions on RussiaMarch 19, 2023 | benzinga.comTurning Point Ministries Welcomes New Chief Development OfficerMarch 14, 2023 | stocknews.com1 Stock to Buy This Week and Hold for the Next 20 YearsMarch 8, 2023 | mirror.co.ukHarry and Meghan's 'whining' Netflix series was 'turning point' with US, says authorMarch 1, 2023 | ft.comWhy 2023 might just be a turning point for climate actionFebruary 26, 2023 | mirror.co.ukBruno Fernandes outlines Man Utd turning point after "really bad" momentFebruary 25, 2023 | seekingalpha.comTurning Point Brands raises dividend by 8% to $0.065February 19, 2023 | msn.comThese 4 major new Indian military inductions mark a positive turning pointFebruary 17, 2023 | theguardian.comIs this Australia’s turning point for concussion in sport?February 17, 2023 | newsweek.comFBI Investigation Into Donald Trump Reaches 'Big Turning Point'January 27, 2023 | marketwatch.comCadrenal Therapeutics Hit Lowest Point Since Friday IPO, Down 21%January 26, 2023 | benzinga.comGermany Agrees To Send Leopard 2 Tanks To Ukraine: Could This Be A Turning Point For The War?January 26, 2023 | finanznachrichten.deBristol Myers Squibb To Acquire Turning Point TherapeuticsJanuary 17, 2023 | fxstreet.comTurning point? Softer US inflation prompts more to dump the DollarJanuary 15, 2023 | washingtonpost.comBiden’s summit with Japanese leader marks a turning pointJanuary 15, 2023 | foxnews.comMSNBC edits column after Turning Point USA sends cease-and-desist letter blasting 'defamatory' commentOctober 17, 2022 | cnbc.comHandicapping whether the stock market is at a turning point after Thursday's upside reversalOctober 7, 2022 | investing.comThe Energy Report: Turning PointSeptember 21, 2022 | ft.comThe Ukraine war has reached a turning pointSeptember 19, 2022 | marketbeat.comTurning Point Therapeutics, Inc. (NASDAQ:TPTX) Given Average Rating of "Hold" by BrokeragesTurning Point Therapeutics, Inc. (NASDAQ:TPTX - Get Rating) has received an average rating of "Hold" from the twelve brokerages that are covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. TheAugust 17, 2022 | marketbeat.comTrading was temporarily halted for "TPTX" at 07:08 PM with a stated reason of "News pending."August 9, 2022 | marketbeat.comTurning Point Therapeutics (NASDAQ:TPTX) Releases Quarterly Earnings Results, Misses Estimates By $0.78 EPSTurning Point Therapeutics (NASDAQ:TPTX - Get Rating) announced its quarterly earnings results on Monday. The company reported ($2.48) earnings per share for the quarter, missing the consensus estimate of ($1.70) by ($0.78). The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $2.27 million. The firm's revenue for the quarter was down 97.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.14) earnings per share.August 8, 2022 | finance.yahoo.comTurning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational UpdatesAugust 3, 2022 | marketbeat.comShort Interest in Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Drops By 25.5%Turning Point Therapeutics, Inc. (NASDAQ:TPTX - Get Rating) was the recipient of a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 2,130,000 shares, a decline of 25.5% from the June 30th total of 2,860,000 shares. Currently, 5.0% of the shares of the company are sold short. Based on an average trading volume of 1,830,000 shares, the short-interest ratio is presently 1.2 days.July 31, 2022 | marketbeat.comTurning Point Therapeutics, Inc. (NASDAQ:TPTX) Receives Consensus Recommendation of "Hold" from BrokeragesShares of Turning Point Therapeutics, Inc. (NASDAQ:TPTX - Get Rating) have been assigned a consensus rating of "Hold" from the twelve brokerages that are currently covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a hold rating and three have assigned a buJuly 29, 2022 | marketbeat.comTurning Point Therapeutics, Inc. (NASDAQ:TPTX) CFO Paolo Tombesi Sells 1,183 SharesTurning Point Therapeutics, Inc. (NASDAQ:TPTX - Get Rating) CFO Paolo Tombesi sold 1,183 shares of the firm's stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $74.94, for a total transaction of $88,654.02. Following the completion of the sale, the chief financial officer now owns 28,700 shares of the company's stock, valued at $2,150,778. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.July 27, 2022 | msn.comTurning Point Secures Positive FDA Feedback For Planned Lung Cancer Drug SubmissionJuly 27, 2022 | finance.yahoo.comTurning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLCJuly 25, 2022 | finance.yahoo.comBristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?July 3, 2022 | marketbeat.comTurning Point Therapeutics, Inc. (NASDAQ:TPTX) Sees Large Drop in Short InterestTurning Point Therapeutics, Inc. (NASDAQ:TPTX - Get Rating) saw a significant drop in short interest during the month of June. As of June 15th, there was short interest totalling 3,020,000 shares, a drop of 26.2% from the May 31st total of 4,090,000 shares. Based on an average daily volume of 1,680,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 7.1% of the shares of the company are short sold.June 24, 2022 | finance.yahoo.comTurning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer TherapiesJune 20, 2022 | marketbeat.comTurning Point Therapeutics (NASDAQ:TPTX) Given a $76.00 Price Target at GuggenheimGuggenheim set a $76.00 target price on Turning Point Therapeutics in a research report on Monday.June 10, 2022 | benzinga.comInvestor Alert - The M&A Class Action Firm Announces an Investigation of Turning Point Therapeutics, Inc. - TPTX Get Turning Point Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Did Intel Just Dethrone Nvidia? (Ad)Intel (INTC) just announced a brand-new AI venture - the Aurora supercomputer. This computer was specifically designed for artificial intelligence and is now the fastest AI-centered computer on the planet. You can get all the details here. TPTX Media Mentions By Week TPTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TPTX News Sentiment▼0.800.57▲Average Medical News Sentiment TPTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TPTX Articles This Week▼00▲TPTX Articles Average Week Get Turning Point Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Crinetics Pharmaceuticals News Insmed News Summit Therapeutics News Biohaven News Axsome Therapeutics News Alkermes News Perrigo News Ultragenyx Pharmaceutical News Prestige Consumer Healthcare News HUTCHMED News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TPTX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsAmerica’s worst nightmare?Porter & CompanyInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperHow to Make 100X on the AI BoomInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turning Point Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
